Future advances in DCIS: de-escalation of hormonal therapy

0 Views
administrator
administrator
07/16/23

Ivana Sestak, PhD, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK, explores the future of treatment of patients with ductal carcinoma in situ (DCIS), including potential de-escalation of endocrine therapy, and the importance of identifying patients who will have an invasive recurrence of disease, namely by using biomarkers that identify with aggressive disease. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next